Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XD5A
|
|||
| Former ID |
DIB006360
|
|||
| Drug Name |
E-101
|
|||
| Synonyms |
Myeloperoxidase; Glucose oxidase; Human myeloperoxidase, dimer; E-101 (infections); Myeloperoxidase formulations (nosocomial infections), Exoxemis; E-101 (infections), Exoxemis; MPO enzyme system (hospital-acquiredl infections), Exoxemis; Myeloperoxidase + glucose oxidase (infections), Exoxemis
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Infectious disease [ICD-11: 1A00-CA43.1; ICD-10: A00-B99] | Phase 3 | [1] | |
| Company |
Exoxemis
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C17H26Cl2N2O3
|
|||
| Canonical SMILES |
CCC1=CC(=C(C(=C1O)C(=O)NCC2CCN(C2)CC)OC)Cl.Cl
|
|||
| InChI |
1S/C17H25ClN2O3.ClH/c1-4-12-8-13(18)16(23-3)14(15(12)21)17(22)19-9-11-6-7-20(5-2)10-11;/h8,11,21H,4-7,9-10H2,1-3H3,(H,19,22);1H/t11-;/m0./s1
|
|||
| InChIKey |
RDZXYWICCLALQM-MERQFXBCSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloperoxidase (MPO) | Target Info | Modulator | [2] |
| KEGG Pathway | Phagosome | |||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| IL23-mediated signaling events | ||||
| WikiPathways | Folate Metabolism | |||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01297959) Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery. U.S. National Institutes of Health. | |||
| REF 2 | In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.